Rewarewa

Rewarewa honey contains arabinogalactan proteins (AGPs), diacyl compounds, and polyphenols including quinic acid, which inhibit neutrophil superoxide production (IC50 4.3 mg/ml) and suppress leukocyte-mediated inflammation. Topical application in a mouse ear oedema model abrogated arachidonic acid-induced swelling and neutrophil infiltration at levels comparable to mānuka honey, representing the strongest preclinical evidence available for this ingredient.

Origin & History

Knightia excelsa is an endemic New Zealand tree belonging to the Proteaceae family, growing naturally throughout the North Island and upper South Island of Aotearoa New Zealand in lowland and montane forests. It thrives in well-drained, moderately fertile soils and is one of the few members of the Proteaceae family native to New Zealand, reaching heights of up to 30 metres. The tree produces distinctive crimson tubular flowers that are a rich nectar source for native birds such as tūī and kererū, and these flowers are also harvested by bees to produce the monofloral honey that has become the primary subject of modern scientific investigation.

Historical & Cultural Context

Knightia excelsa holds significance in Māori traditional medicine (rongoā Māori), where the leaves were used to relieve coughing, representing one of the documented applications of this endemic tree in indigenous health practice in Aotearoa New Zealand. The tree's Māori name 'rewarewa' is well established in New Zealand botanical and cultural lexicons, and the species is considered taonga (treasured) as part of the native forest ecosystem that Māori communities have long managed and inhabited. The crimson flowers of rewarewa attracted native birds central to Māori ecological and cultural life, and the tree's honey-producing capacity — exploited by introduced European honeybees — has given it renewed contemporary significance as a premium New Zealand monofloral honey. Detailed historical records of specific preparation methods, ceremonial use, or broader pharmacopoeia classification within rongoā Māori are limited in currently available literature, underscoring the need for deeper ethnobotanical documentation in collaboration with iwi knowledge holders.

Health Benefits

- **Anti-inflammatory Activity**: Rewarewa honey inhibits neutrophil superoxide production in vitro at an IC50 of 4.3 mg/ml and reduces ear oedema and leukocyte infiltration in vivo in mouse models, with diacyl compounds proposed as the primary active contributors.
- **Antibacterial Properties**: At 25% concentration, rewarewa honey demonstrates antibacterial activity against a range of bacteria, attributed to arabinogalactan proteins (AGPs) and polyphenolic constituents rather than hydrogen peroxide or methylglyoxal pathways.
- **Antioxidant Capacity**: Polyphenolic compounds in rewarewa honey produce measurable antioxidant activity across multiple assays (CUPRAC 0.244, FRAP 0.320, DPPH 0.155 at 12.50% concentration), indicating moderate free radical scavenging capability.
- **Respiratory Support (Traditional)**: Māori healers traditionally used leaves of Knightia excelsa to relieve coughing, representing one of the earliest documented therapeutic applications of this plant within indigenous Aotearoa medicine.
- **Neutrophil Modulation**: Beyond simple antioxidant action, rewarewa honey appears to interfere with neutrophil activation pathways independently of direct reactive oxygen species quenching, suggesting a receptor-level or signalling-mediated mechanism relevant to inflammatory disease management.
- **Polyphenol Delivery**: Rewarewa honey-derived food products such as ice cream contain significantly high concentrations of quinic acid, a bioactive polyphenol with documented antioxidant and potential neuroprotective properties, indicating the honey as a functional polyphenol source.

How It Works

Rewarewa honey inhibits neutrophil superoxide production independently of direct free radical scavenging and independently of xanthine/xanthine oxidase-derived superoxide, indicating that its anti-inflammatory action targets neutrophil activation signalling rather than acting as a simple antioxidant. The diacyl compounds present at high concentrations in rewarewa honey are proposed as the candidate molecules responsible for this effect, potentially interfering with NADPH oxidase assembly or upstream neutrophil priming pathways, though precise receptor or enzyme targets have not yet been characterised. In vivo, topical rewarewa honey reduces leukocyte infiltration and tissue oedema in arachidonic acid-challenged mouse ears, with the primary cellular effect being suppression of neutrophil influx; this is hypothesised to occur via modulation of resident tissue cell signalling or inhibition of neutrophil self-recruitment chemotactic loops. Arabinogalactan proteins (AGPs), detected at moderate levels in rewarewa honey, may contribute to antibacterial activity through disruption of bacterial cell surface interactions, a mechanism increasingly documented for AGP-rich honeys.

Scientific Research

The available scientific evidence for rewarewa (Knightia excelsa) and its honey is limited exclusively to in vitro and in vivo preclinical studies; no human clinical trials have been conducted or registered as of current available data. Key in vitro findings include neutrophil superoxide inhibition with an IC50 of 4.3 mg/ml from a single honey sample (n=1 sample), which falls within the range reported for mānuka and kānuka honeys (3.1–6.1 mg/ml), providing a useful but preliminary benchmark. In vivo evidence derives from topical application experiments in C57BL/6J mice using arachidonic acid-induced ear inflammation, where rewarewa honey (designated H21) significantly abrogated oedema and leukocyte infiltration, with results comparable to mānuka honey (H10), though specific animal group sizes were not reported in available summaries. Antioxidant profiling across multiple validated assay systems (CUPRAC, FRAP, DPPH, TFC, TPC) places rewarewa honey at an intermediate position among New Zealand monofloral honeys, providing consistent physicochemical characterisation but no clinical outcome data.

Clinical Summary

No human clinical trials have been completed for rewarewa honey or Knightia excelsa plant extracts in any therapeutic indication, meaning all clinical inferences must be drawn cautiously from preclinical models. The most robust preclinical data concerns topical anti-inflammatory efficacy in a validated mouse ear oedema model, where rewarewa honey abrogated arachidonic acid-induced inflammation with potency comparable to mānuka honey, which itself has a broader but still limited clinical evidence base. In vitro antibacterial testing at 25% concentration and neutrophil superoxide suppression (IC50 4.3 mg/ml) provide supportive mechanistic data, but effect sizes in human tissues and therapeutic dose equivalents cannot be extrapolated without controlled human studies. Overall confidence in clinical benefit is low due to the absence of randomised controlled trials, standardised extract preparations, defined dose ranges, and pharmacokinetic data in humans.

Nutritional Profile

Rewarewa honey, as a food product, shares the general macronutrient profile of honey — predominantly simple sugars (fructose and glucose comprising approximately 65–80% of dry weight) with negligible protein and fat content. Its most pharmacologically relevant constituents are polyphenols, with quinic acid present at significantly elevated concentrations in rewarewa honey-derived products, alongside a broader polyphenolic pool contributing to a total phenolic content (TPC) of 1.853 (units at 12.50% concentration in standardised assay). Arabinogalactan proteins (AGPs) are detected at moderate levels, lower than those found in kānuka, kāmahi, pōhutukawa, and mānuka honeys, and these glycoproteins contribute to both viscosity and biological activity. Methylglyoxal (MGO), the principal antibacterial compound in mānuka honey, is absent or undetectable (0 mg/kg) in rewarewa honey, distinguishing its antibacterial mechanism as polyphenol- and AGP-dependent rather than MGO-dependent; bioavailability of honey polyphenols is generally considered moderate and influenced by gut microbiome composition.

Preparation & Dosage

- **Raw Monofloral Honey (Oral)**: No clinically established dose; traditional and anecdotal use follows general honey conventions of 1–2 teaspoons (5–10 ml) for throat and cough relief, consistent with Māori use of the plant for coughing.
- **Topical Honey Application**: Preclinical mouse studies applied honey directly to tissue surfaces; no standardised human topical dose or formulation protocol has been established.
- **In Vitro Reference Concentrations**: Antibacterial activity observed at 25% w/v; antioxidant profiling conducted at 12.50% concentration; neutrophil inhibition IC50 determined at 4.3 mg/ml — these are laboratory reference points, not supplement dosing guidelines.
- **Traditional Leaf Preparation**: Māori traditional use involved leaves of Knightia excelsa for cough relief; specific preparation method (infusion, decoction, or direct application) is not documented in available ethnobotanical records.
- **Standardised Extracts or Capsules**: No commercially standardised extracts, capsules, or tinctures of rewarewa leaf or honey are currently available; the honey is consumed as a whole food product rather than a concentrated supplement.

Synergy & Pairings

Rewarewa honey may exhibit complementary activity when combined with other AGP-rich New Zealand honeys such as kānuka or mānuka, as the combination of AGP-mediated immune modulation with mānuka's methylglyoxal-dependent antibacterial pathway could address a broader antimicrobial and anti-inflammatory spectrum than either honey alone. The polyphenol quinic acid present in rewarewa honey may synergise with vitamin C, as quinic acid is a metabolic precursor to hippuric acid pathways and its antioxidant activity can be potentiated in the presence of ascorbic acid, a combination relevant to respiratory health applications. For cough and throat applications consistent with traditional Māori use, pairing rewarewa honey with mucilaginous herbal preparations such as marshmallow root (Althaea officinalis) could offer complementary demulcent and anti-inflammatory activity, though no experimental data for this specific combination exists.

Safety & Interactions

No adverse effects, drug interactions, or contraindications specific to rewarewa honey or Knightia excelsa plant extracts have been reported in the scientific literature, and mouse topical application studies noted no observed toxicity. Standard honey contraindications apply: rewarewa honey should not be administered to infants under 12 months due to the universal risk of Clostridium botulinum spore germination in the immature gut microbiome. Individuals with known bee-product allergies (including pollen or propolis sensitivities) should exercise caution with any monofloral honey, including rewarewa, as allergenic proteins from floral sources may be present. No formal toxicology studies, maximum tolerated dose data, reproductive toxicity assessments, or drug interaction evaluations exist for rewarewa honey or plant extracts, meaning safety in pregnancy, lactation, paediatrics, and polypharmacy contexts cannot be formally characterised beyond general honey guidance.